Issue 3.13
Sustainability has become a paramount consideration for global industries seeking to find a balance between meeting the needs of the current population without compromising future generations...
Issue 3.12
With an increasing proportion of niche therapies entering the development pipeline, the bio/pharma industry is having to pivot to more agile processes that work for smaller batch sizes..
INTERPHEX 2026
As industry sharpens its focus on personalized medicine and orphan drugs, manufacturers are being required to adapt to the new process requirements of these more niche drugs...
Issue 3.11
For many years, the bio/pharma supply chain was operated primarily around cost optimization, which resulted in consolidation of API and raw material sourcing into a handful of global…
Issue 3.10
For decades, the bio/pharmaceutical industry operated with a scale-up philosophy, which led to companies building increasingly massive facilities, housing large-volume stainless-steel bioreactors, to meet global demand for biologics...
Issue 3.9
Advanced therapy medicinal products (ATMPs) are groundbreaking, innovative treatments for many patients once considered untreatable...
DCAT 2026
Since the first DCAT Annual Dinner, which was held in 1926, New York City has played host to the multifaceted global event, DCAT Week...
Issue 3.8
Thanks to the foundational work of the Human Genome Project, which was completed over two decades ago in 2003, biopharmaceutical research and development has made great strides forward...
Issue 3.7
Traditional blockbuster therapies — high-volume, broad-scope drugs — are being rapidly superseded by high-precision, niche therapeutic platforms that target specific genetic pathways...
Issue 3.6
Traditionally, randomized controlled trials (RCTs) have been thought of as the gold standard when it comes to demonstrating the efficacy of an investigational drug product...
Issue 3.5
The clinical trial sector is currently experiencing an evolution thanks to various technological and approach innovations that is equivalent to the transition from paper to Electronic Data Capture…
Issue 3.4
The margin for error within drug development is becoming ever narrower, as R&D costs continue to rise, competition pressures intensify, and regulatory expectations grow…
